Related Experiment Video
Updated: Jun 22, 2025
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali1, Greta Bagnolini2, Andrea Ciamarone1,2
1Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Abstract:
In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer therapies. The discovery of a growing number of synthetic lethal targets has led to a significant expansion in the use of synthetic lethality, far beyond poly(ADP-ribose) polymerase inhibitors used to treat BRCA1/2-defective tumors. In particular, molecular targets within DNA damage response have provided a source of inhibitors that have rapidly reached clinical trials. This Perspective focuses on the most recent progress in synthetic lethal targets and their inhibitors, within and beyond the DNA damage response, describing their design and associated therapeutic strategies. We will conclude by discussing the current challenges and new opportunities for this promising field of research, to stimulate discussion in the medicinal chemistry community, allowing the investigation of synthetic lethality to reach its full potential.
Insights
Synthetic lethality offers a promising anticancer therapy approach. Recent advances expand its use beyond DNA repair targets, presenting new therapeutic strategies and opportunities for drug development.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Synthetic lethality is a validated strategy for developing novel anticancer therapies.
- The application of synthetic lethality has significantly broadened, extending beyond poly(ADP-ribose) polymerase inhibitors for BRCA1/2-mutated cancers.
- Molecular targets within DNA damage response pathways are a key focus for new inhibitor development.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in synthetic lethal targets and their inhibitors.
- To discuss the design of these inhibitors and associated therapeutic strategies.
- To highlight current challenges and future opportunities in synthetic lethality research.
Main Methods:
- Review of recent scientific literature on synthetic lethality.
- Analysis of emerging synthetic lethal targets and inhibitor development.
- Discussion of therapeutic strategies and clinical trial progress.
Main Results:
- Significant progress has been made in identifying and targeting synthetic lethal interactions.
- Numerous inhibitors targeting DNA damage response pathways have advanced to clinical trials.
- The scope of synthetic lethality is expanding to include targets beyond DNA repair.
Conclusions:
- Synthetic lethality represents a rapidly evolving field with substantial therapeutic potential.
- Continued research into novel synthetic lethal targets and inhibitors is crucial.
- Addressing current challenges will unlock the full potential of synthetic lethality in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...